-
A New Generation of Drug Therapies Requires New Business Strategies
Operations and supply chain management Digital ArticleThe shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management. -
Moderna v. Pfizer: What the Patent Infringement Suit Means for Biotech
Business and society Digital ArticleAfter an unusual period of cooperation, drug companies are suing each other again. -
A Debt of Gratitude
Magazine ArticleHighlights from this issue -
Addressing Demographic Disparities in Clinical Trials
R&D Digital ArticleWomen, people of color, and the elderly are often underrepresented in the data. -
The CEO of Pfizer on Developing a Vaccine in Record Time
Collaboration and teams Magazine ArticleIt started with a moon-shot challenge. -
White Coats, Black Scientists
Race Digital ArticleHow scientific institutions can address systemic racism. -
What It Takes to Lead a Disease Research Foundation
Leadership and managing people Digital ArticleThree strategies to stay laser focused on the path to a cure. -
Where Telemedicine Falls Short
Technology and analytics Digital ArticleIt offers enormous benefits — but can’t replace in-person visits. -
It’s Time for a New Kind of Electronic Health Record
Analytics and data science Digital ArticleWe need to shift from reactive to preventative care. -
How Medical Nonprofits Set Winning Strategy
Strategy Digital ArticleA study of nearly 100 organizations. -
Adopting AI in Health Care Will Be Slow and Difficult
Technology and analytics Digital ArticleA few key obstacles and how to overcome them. -
The Future of Drug Trials Is Better Data and Continuous Monitoring
R&D Digital ArticleIt will help patients and bring new treatments to market faster. -
3 Business Models That Could Bring Million-Dollar Cures to Everyone
Innovation Digital ArticleGene therapy is a medical breakthrough, but today it’s prohibitively expensive. -
Sexual Harassment Is Rampant in Health Care. Here’s How to Stop It.
Corporate governance Digital ArticleFive steps health organizations can take. - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN
Why the Pharmaceutical Industry is Booming in Japan
Government policy and regulation Sponsor ContentOlder people need more medicine. That rule of life is no secret to pharmaceutical companies across the globe. Many also realize that Japan’s rapidly aging population presents a unique business opportunity. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The Japanese market also is expected to grow annually. […] -
“Businesses Exist to Deliver Value to Society.”
R&D Magazine ArticleA conversation with Merck CEO Kenneth Frazier - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN
How Japan Is Creating New Opportunities in the Field of Regenerative Medicine
Economics Sponsor ContentAs biotech companies race toward the opportunities in Japan, no life sciences sector has received more attention, government support, and regulatory reform than the important field of regenerative medicine. Regeneratives are pharmaceutical cell therapy products that replace or restore cells and tissues lost to disease or aging. Some regenerative medicines stimulate our bodies to regrow […] -
A New Approach to Safely Sharing Cancer Patients’ Data
Corporate social responsibility Digital ArticleBetter treatment depends on it. -
Conflict-of-Interest Rules Are Holding Back Medical Breakthroughs
Business ethics Digital ArticleResearchers and companies have to work together. -
How Pharma Companies Game the System to Keep Drugs Expensive
Government policy and regulation Digital ArticleThe promise of generics remains unfulfilled.
-
Changing Diabetes in Children: A public-private partnership delivering diabetes care to children in low- and middle-income countries
Business and society Case Study11.95View Details Addressing the consequences of type 1 diabetes (T1D) in low- and middle-income countries (LMICs) is a formidable challenge. Many children do not receive... -
Chugai (B): Alliance with Roche to be among the best
International business Case Study5.00View Details Chugai B examines the pivotal strategic alliance formed in October 2002 between Chugai Pharmaceutical and Swiss giant Roche. Facing constraints in RD... -
Chugai (C): Navigating the next century of global innovation
International business Case Study5.00View Details Chugai C focuses on the company's future as it celebrates its 100th anniversary in 2025. In 2021, Chugai launched its ambitious 'TOP I 2030' growth strategy,... -
Chugai (A): Overcoming adversity with a transformative leap
International business Case Study11.95View Details Chugai A traces the transformative journey of a leading Japanese biopharmaceutical firm from its founding in 1925 to the early 2000s. Starting with founder... -
Aspen Pharmacare: International Strategy for an African Champion
Competitive strategy Case Study11.95View Details This case is about the evolution of the business model of Aspen, a pharmaceutical company from South Africa. Aspen has successfully grown from a company... -
Sanofi: Dosing the Cost of Capital
Corporate finance Case Study11.95View Details At a pension fund that has a large position in Sanofi, a leading global pharmaceutical company, intern Rafael Perez has been asked to help equity analyst... -
Eli Lilly and Indiana's Innovation Strategy
Innovation Case Study11.95View Details Between 2022 and 2025, Eli Lilly announced over $13 billion in investments in central Indiana's LEAP Innovation District-the largest commitment in the... -
Eli Lilly: Weighing Options in the Obesity Drug Market (Abridged)
Marketing Case Study11.95View Details In May 2025, the pharmaceutical company Eli Lilly seemed to be pulling ahead in the lucrative obesity drug market. Its GLP-1 drug, Zepbound, had gained... -
Sandoz (B): The art of staying true to your mission
Boards Case Study5.00View Details This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case B looks at Sandoz once it has become independent.... -
Sandoz (A): Breaking free to stand alone
Boards Case Study11.95View Details This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case A follows Richard Saynor's (CEO, Sandoz) ruminations... -
Sandoz China: Do we stay or do we go?
Mergers and acquisitions Case Study11.95View Details The Sandoz leadership team faced an important decision as it broke away from Novartis and became a public company. Should Sandoz retain the global geographical... -
Does America Need a New Supply Chain?
Supply chain management Case Study11.95View Details In April 2025, Aaron Sneed, founder of Defense Operations & Engineering Solutions Inc. (DOES), confronted a mounting crisis as US-China trade tensions... -
To Approve or Not to Approve? That Is the Question: The FDA's Decision on a New Alzheimer's Drug
Business and society Case Study11.95View Details The case asks students to help Dr. Cavazzoni make an important decision: to concur with the FDA staff's recommendation for accelerated approval or agree... -
Insilico's Rentosertib Dilemma: A Star in the Pipeline?
AI and machine learning Case Study11.95View Details In 2024, the AI biotech firm Insilico Medicine faced a pivotal decision about its new drug, Rentosertib. Discovered and designed using artificial intelligence... -
Rejuvenate Bio: Turning Back the Biological Clock
Entrepreneurial business strategy Case Study11.95View Details The case traces the journey of Daniel Oliver and Noah Davidsohn, founders of Rejuvenate Bio, a biotech company developing gene therapies for age-related... -
Junshi: From Domestic Breakthroughs to Global Strategy in Biopharma
Competitive strategy Case Study11.95View Details Junshi Pharmaceuticals was founded in 2012 in Shanghai by five technical professionals formerly employed at multinational pharmaceutical companies, with... -
AI Wars in 2025
AI and machine learning Case Study11.95View Details In June 2025, Google leaders in Mountain View, CA convened after its parent company Alphabet shed a quarter-trillion in market capitalization in a matter... -
GlaxoSmithKline: Prepping for Battle
Case Study11.95View Details In 2021, the pharmaceutical giant GlaxoSmithKline plc was considering going beyond its existing line of treatment drugs for HIV and AIDS and enter the... -
A Vaccine to Save the World? Pascal Soriot's Leadership Challenge
Business ethics Case Study11.95View Details This case follows the development of the AstraZeneca-Oxford vaccine from its origins in an Oxford University laboratory, through an accelerated series... -
Vertex Pharmaceuticals
Case Study11.95View Details
